Investigating the intratumoural microbiome in young-onset CRC patients
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
List view / Grid view
Articles
SARS-CoV-2 viral peptide fragments cause serious inflammatory response
In this Q&A, Dr Gerard Wong elucidates the inflammatory capacity of fragmented viral components from the perspective of supramolecular self-organisation.
The great prostate debate: innovations in prostate cancer screening
While blood tests measuring prostate-specific antigen (PSA) levels have been a primary screening tool, their limitations in specificity have led to challenges such as overdiagnosis and overtreatment. Cleveland Diagnostics is pioneering an alternative approach with the IsoPSA test, focusing on assessing the structure of the PSA protein rather than its…
Understanding how macrophages direct tissue regeneration
Distinct macrophage signatures that align specifically with regeneration could offer novel therapies to enhance wound healing.
How 3D human tissue models are transforming drug discovery
In this Q&A, Keith Murphy, CEO of Organovo, discusses how the shift from animal models to 3D human tissues can transform the preclinical space. Among his many insights, he details the limitations of animal models, how Organovo’s 3D human tissue models facilitate a deeper understanding of genetic expression within specific…
Advancing neurological therapies with Dr Bruce Leuchter
In the world of neuroscience, where the unmet medical need is vast and diverse, the journey to develop and commercialise treatments for neurological diseases, including rare conditions, is fraught with challenges. In this insightful interview with Dr Bruce Leuchter, President and CEO at Neurvati Neurosciences, with over two decades of…
Women in Stem with Dr Sara Sangha
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. This month we interview Dr Sara Sangha, Associate Vice President of Medical Affairs and Head of US Medical Aesthetics at AbbVie. Over her almost 20 years with Allergan…
The promise of 3A5C7 mAb in the treatment of morphine tolerance
Morphine is a frequently used analgesic that activates the mu-opioid receptor (MOR), which has prominent side effects of tolerance. A monoclonal antibody (mAb) precisely targeting MOR, named as 3A5C7, was developed to treat morphine tolerance by enhancing morphine-induced MOR endocytosis via GRK2/β-arrestin2 pathway. In this Q&A session with Dr Jia-Jia…
SARS-CoV-2: advancing the production of the ACE2 protein
Producing functional human ACE2 protein in mouse cells provides a new way to study the receptor used by the SARS-CoV-2 spike protein.
Therapeutic peptide developed for triple-negative breast cancer
Scientists demonstrate how disrupting the Cx26 molecular complex in triple-negative breast cancer cells slowed tumour growth.
RNA interference and its role in Alzheimer’s disease
New data provides an explanation for why, in almost all neurodegenerative diseases, disease sets in as cells age.
Immuno-oncology innovations redefining cancer treatment in 2024
In this exclusive interview, Dr Espen Basmo Ellingsen, a luminary in cancer immunology, provides insights into the anticipated breakthroughs, collaborative endeavours, and personalised strategies that promise to elevate the effectiveness and durability of immuno-oncology interventions.
Mechanisms underlying pioneer TF-mediated gene repression
Researchers have made surprising and important findings that may influence organoid and cell reprogramming studies.
Women in Stem with Dr Mrunal Jaywant
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. We had the privilege of interviewing Dr Mrunal Jaywant, Vice President of R&D at USP India. At USP India, Dr Jaywant oversees the Compendial Development, the Synthetic Chemistry,…
Using proteomics to overcome glioblastoma resistance
Using an AI algorithm to predict glioblastoma’s most active kinase, researchers hope for a next-generation precision therapy targeting resistant cancers.